Sanofi finishes Genzyme deal, weighs name change

Having wrapped up its acquisition of Genzyme with 84.6 percent of stock tendered, Sanofi-Aventis says the contingent value rights associated with the deal will begin trading--and that it's considering changing its name simply to "Sanofi," to make it easier to pronounce in international markets. Report | Report